Targeted therapy for advanced renal cell cancer: cytokines and beyond.

@article{Papaetis2008TargetedTF,
  title={Targeted therapy for advanced renal cell cancer: cytokines and beyond.},
  author={George S Papaetis and Lena M Karapanagiotou and Hardev Pandha and Konstantinos Syrigos},
  journal={Current pharmaceutical design},
  year={2008},
  volume={14 22},
  pages={
          2229-51
        }
}
For the past 20 years cytokines have been the mainstay of treatment for advanced renal cell cancer (RCC), despite low response rates achieved and the high toxicity profile observed. The recent advances in molecular biology and the greater understanding of the von Hippel-Lindau (VHL) hypoxia-inducible factor (HIF)-hypoxia-induced gene pathway have paved the… CONTINUE READING